Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
filingDate |
2014-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2020-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-102134056-B1 |
titleOfInvention |
Combination of vaccination and inhibition of the PD-1 pathway |
abstract |
The present invention provides an RNA vaccine comprising at least one RNA comprising an open reading frame (ORF) encoding at least one antigen and at least one PD-1 pathway inhibitor, preferably PD-1 receptor or ligand PD- thereof A vaccine/inhibitor combination comprising a composition comprising a PD-1 pathway inhibitor for L1 and PD-L2. The invention also relates to pharmaceutical compositions and kits of parts comprising components of such vaccine/inhibitor combinations. The present invention also provides such vaccine/inhibitor combinations, pharmaceutical compositions and kits of kits, including such vaccine/inhibitor combinations, particularly vaccine/inhibitor combinations for the prevention or treatment of tumor or cancer diseases or infectious diseases. of parts). The present invention also relates to the use of RNA vaccines for use in treatment in combination with PD-1 pathway inhibitors and the use of PD-1 pathway inhibitors for use in treatment in combination with RNA vaccines. |
priorityDate |
2013-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |